Why AstraZeneca Is Likely On Pfizer's Back Burner, For Now
Speculation has yet again kicked up over whether growth-hungry Pfizer Inc. will make a second run at AstraZeneca PLC after its $118 billion bid fell flat earlier this year, but the...To view the full article, register now.
Already a subscriber? Click here to view full article